Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 24, 2026
Why Is Cerebras Systems (CBRS) Stock Down -7.05% Today?

Why Is Cerebras Systems (CBRS) Stock Down -7.05% Today?

Key Takeaways

  • Cerebras Systems shares fell 7.05% to $204.50 on Thursday, erasing most of the gains from the prior session's AMD partnership rally.
  • Profit-taking dominated after a steep ~27% surge over the preceding week, as traders locked in gains following back-to-back partnership announcements with CrowdStrike and AMD.
  • Broader AI sector jitters weighed on sentiment, with investors growing increasingly selective about AI infrastructure names amid concerns over the pace and profitability of hyperscaler spending.
  • Persistent fundamental concerns — including declining gross margins, heavy infrastructure costs tied to the OpenAI contract, and customer concentration risk — continued to hang over the stock.
  • Traders are now watching for the company's Q2 earnings report expected in August, as well as any updates on data center capacity buildout and AWS deployment timelines.

Opening Summary

Shares of CBRS, the AI infrastructure company known for its pioneering wafer-scale processor technology, tumbled 7.05% in Thursday's trading session to $204.50, surrendering a substantial portion of the prior day's advance. The drop followed a closing price of $220.00 on Wednesday, when the stock rallied nearly 5% on news of a technical partnership with AMD. Cerebras Systems, which went public in May 2026 at $185 per share, has experienced extreme volatility since its IPO, trading as high as $386.34 on its first day before falling below $161 in late June. Thursday's selloff reflects a combination of profit-taking after a sharp multi-day rally and renewed scrutiny of the company's near-term profitability trajectory.

Profit-Taking After a Torrid Multi-Day Rally

The most immediate driver behind Thursday's decline is straightforward: traders who rode the stock higher during its blistering ~27% surge from $172.86 on July 17 to $220.00 on July 23 are cashing out. That rally was fueled by two high-profile partnership announcements in rapid succession — first with CRWD on July 22, in which CrowdStrike agreed to use Cerebras' inference infrastructure to power its Falcon AI Detection and Response product, and then with AMD on July 23, unveiled at AMD's Advancing AI 2026 conference, integrating Cerebras' Wafer-Scale Engine into AMD's Helios rackscale systems.

The pattern of partnership-driven spikes quickly fading is not new for CBRS. Following the CrowdStrike announcement on July 22, the stock surged as much as 18% intraday to $244 before closing at $209.80, surrendering more than half those gains in a single session. Thursday's pullback extends that "buy the rumor, sell the news" dynamic, as the market digests that while these partnerships validate Cerebras' technology, neither came with disclosed revenue figures, contract sizes, or exclusivity terms that would materially alter near-term financials.

Margin Concerns and Execution Risk Linger

Beneath the headline-driven volatility, fundamental worries about Cerebras' profitability path continue to weigh on investor sentiment. In its first quarterly report as a public company, CBRS delivered impressive top-line growth — revenue surged 94% year-over-year to $193.4 million — but management's gross margin guidance spooked the market. The company guided for Q2 adjusted gross margin of 36% to 38%, a sharp sequential decline from 47% in Q1, and full-year 2026 gross margin of just 38% to 41%.

The compression stems from Cerebras' aggressive infrastructure buildout to service its landmark agreement with OpenAI, valued at more than $20 billion for 750 megawatts of AI inference capacity. Management disclosed it is temporarily renting back systems from existing customers to accelerate cloud capacity deployment, a stopgap that inflates near-term costs. While the company expects margins to recover once its own data centers come online — with new facilities anticipated in the second half of 2026 — the timeline remains uncertain, and investors are increasingly demanding proof of execution rather than promises.

Broader AI Sector Reassessment

Thursday's selloff in CBRS also unfolded against a backdrop of cooling enthusiasm across the AI semiconductor space. The market is transitioning from a phase where any AI-related headline attracted aggressive buying to one where investors are demanding concrete earnings delivery relative to elevated valuations. Reports of jitters over GOOG / GOOGL AI spending plans and broader questions about the return on massive infrastructure investments have created headwinds for the entire sector. With CBRS trading at a lofty price-to-sales multiple and still reporting GAAP losses, it remains particularly vulnerable when risk appetite contracts.

Market Context and Trading Activity

Thursday's decline came with elevated trading volume, consistent with the pattern of heightened turnover that has characterized CBRS shares since the IPO. The stock's average daily volume over the past several weeks has run well above typical levels for a mid-cap semiconductor name, reflecting the intense speculative interest in the AI infrastructure theme. The move lower pushed the stock back below the $210 level, which had acted as resistance during the July 21 session before being broken. The stock remains more than 43% below its all-time high of $386.34 and roughly 10% above its late-June trough near $161.

What Comes Next for CBRS

Looking ahead, the next major catalyst for CBRS will be its second-quarter earnings report, which Robinhood indicates is expected around August 12. Investors will be laser-focused on gross margin trajectory, any revisions to the full-year outlook, and concrete updates on data center capacity expansion and AWS deployment progress. Additionally, the looming insider lock-up expiration — which features unconventional early-unlock clauses triggered if market capitalization exceeds $40 billion — represents a potential overhang. On the positive side, the company's approximately $25 billion in remaining performance obligations provides exceptional revenue visibility, and 11 analysts tracked by S&P Global maintain a consensus "Strong Buy" rating with an average price target of $291.09. Whether CBRS can convert its partnership momentum and massive backlog into sustained shareholder returns remains the central question.

Trending AI Robots

For traders seeking a data-driven edge in navigating volatile names like CBRS, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving market conditions. Tickeron provides hundreds of automated trading bots spanning thousands of tickers across different strategies, timeframes, and performance metrics. Only the strongest performers under current market conditions are featured in the Trending AI Robots section, giving traders a dynamic window into which algorithms are successfully reading today's market. Bots vary by approach — from swing trading to trend following — and each is transparent about its historical performance and traded symbols. Visit the Trending AI Robots page to explore which strategies are currently outperforming.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CBRS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Broadcom Inc. (NASDAQ:AVGO), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), Micron Technology (NASDAQ:MU), Advanced Micro Devices (NASDAQ:AMD), Intel Corp (NASDAQ:INTC), Texas Instruments (NASDAQ:TXN), Marvell Technology (NASDAQ:MRVL), Analog Devices (NASDAQ:ADI), QUALCOMM (NASDAQ:QCOM).

Industry description

The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.

Market Cap

The average market capitalization across the Semiconductors Industry is 187.57B. The market cap for tickers in the group ranges from 13.43K to 5.31T. NVDA holds the highest valuation in this group at 5.31T. The lowest valued company is CYBL at 13.43K.

High and low price notable news

The average weekly price growth across all stocks in the Semiconductors Industry was 7%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 43%. SITM experienced the highest price growth at 30%, while ON experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Semiconductors Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -31% and the average quarterly volume growth was -62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 53
Price Growth Rating: 48
SMR Rating: 75
Profit Risk Rating: 73
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry Semiconductors

Profile
Details
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.